reports
Ingredion Incorporated Declares Quarterly Dividend of $0.78 per Share
Ingredion Incorporated Declares Quarterly Dividend of $0.78 per Share WESTCHESTER, Ill., May 15, 2024 (GLOBE NEWSWIRE) -- Today, the board of directors of Ingredion Incorporated (NYSE: INGR) declared a quarterly dividend of $0.78 per share on the Company’s common stock. The dividend is payable on July 23, 2024, to stockholders of record at the close of business on July 1, 2024. About the CompanyIngredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in nearly 120 countries. With 2023 annual net sale...
Robinhood Markets, Inc. Reports April 2024 Operating Data
Robinhood Markets, Inc. Reports April 2024 Operating Data MENLO PARK, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for April 2024: Funded Customers at the end of April were 24.0 million, up approximately 90 thousand from March 2024.Assets Under Custody (AUC) at the end of April were $123.3 billion, down 5% from March 2024. Net Deposits were $4.9 billion in April, translating to a 45% annualized growth rate relative to March 2024 AUC. Over the last twelve months, Net Deposits were $27.4 billion, ...
Envoy Medical Reports First Quarter 2024 Results
Envoy Medical Reports First Quarter 2024 Results The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate...
Spero Therapeutics Announces First Quarter 2024 Operating Results and ...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...
Snail, Inc. Reports First Quarter 2024 Financial Results
Snail, Inc. Reports First Quarter 2024 Financial Results CULVER CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Snail, Inc. (NASDAQ: SNAL) (“Snail” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, today announced financial results for its first quarter ended March 31, 2024. Tony Tian, Co-Chief Executive Officer commented, “I'm absolutely thrilled and humbled to take the helm as Co-CEO of Snail. This Company has an exceptionally talented team, ground-breaking technologies, and iconic franchises, like ARK, that have fostered pass...
Merit Medical Executive Leadership Team Update
Merit Medical Executive Leadership Team Update Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit’s global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over ...
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and ...
STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the fir...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Finan...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic hea...
PainReform Provides Business Update for the First Quarter of 2024
PainReform Provides Business Update for the First Quarter of 2024 Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2024. Ilan Hadar, Chief Executive Officer of PainReform, stated, “We are ...
Dave to Participate in the FT Partners Equity Research Weekly Forum on...
Dave to Participate in the FT Partners Equity Research Weekly Forum on May 17th LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, today announced that the Company will participate in the upcoming virtual FT Partners Equity Research Weekly Forum being held on Friday, May 17, 2024. Dave Founder and CEO Jason Wilk and CFO Kyle Beilman will participate in a fireside chat at 10:30 a.m. ET followed by a question-and-answer period. To request details to view the live event, please email FT Partners at or emai...
Hawkins, Inc. Declares Quarterly Cash Dividend of $0.16 Per Share
Hawkins, Inc. Declares Quarterly Cash Dividend of $0.16 Per Share ROSEVILLE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Hawkins, Inc. (Nasdaq: HWKN), at its meeting on May 15, 2024, declared a quarterly cash dividend of $0.16 per share payable June 14, 2024, to shareholders of record at the close of business on May 31, 2024. Hawkins has consistently paid out a dividend since 1985. About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends, and manufactures products for...
CDT Environmental Technology Investment Holdings Limited Files Annual ...
CDT Environmental Technology Investment Holdings Limited Files Annual Report on Form 20-F Reports Second Consecutive Year of Revenue Growth and Profitability SHENZHEN, China, May 15, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) (“CDT”), a leading provider of waste treatment systems and services throughout China, today announces that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2024. The annual report on Form 20-F, which co...
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provi...
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ358 Continue to engage in productive interactions with FDA towards resolution of partial clinical holds and path forward for potential late-stage, registrational, clinical study in tumor hyperinsulinism (HI) REDWOOD ...
Cullinan Therapeutics Provides Corporate Update and Reports First Quar...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, ...
Barfresh Provides First Quarter 2024 Results and Business Update
Barfresh Provides First Quarter 2024 Results and Business Update Record Quarterly Revenue and First Positive Adjusted EBITDA In Company History Highlight Strong First Quarter of 2024 Results Revenue Increased 35% Year-Over-Year to $2.8 Million for the First Quarter of 2024 Achieves 41.4% First Quarter of 2024 Gross Margin - Highest Point Since Early 2021 Company Poised to Achieve Highest Annual Revenue in Fiscal Year 2024 and Year-over-Year Margin Improvement Amid Bottling Recovery Efforts, Propelled by Accelerated Customer Wins LOS ANGELES, May 15, 2024...
TOMI Environmental Solutions, Inc. Reports First Quarter 2024 Financia...
TOMI Environmental Solutions, Inc. Reports First Quarter 2024 Financial Results FREDERICK, Md., May 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter ended March 31, 2024. TOMI Chief Executive Officer, Dr. Halden Shane, stated, “Although revenue was below expectation in the first quarter, we saw continued growth in our...
Davis Commodities Limited Announces Fiscal Year 2023 Financial Results
Davis Commodities Limited Announces Fiscal Year 2023 Financial Results SINGAPORE, May 15, 2024 (GLOBE NEWSWIRE) -- Davis Commodities Limited (Nasdaq: DTCK) (the "Company" or "Davis Commodities"), an agricultural commodity trading company that specializes in trading sugar, rice, and oil and fat products, today announced its financial results for the fiscal year ended December 31, 2023. Ms. Li Peng Leck, Executive Chairwoman and Executive Director of Davis Commodities, commented, “I’m glad to present our financial results for fiscal year 2023. During this period, our business has maintaine...
FormFactor Again Named One of THE BEST Suppliers in the Semiconductor ...
FormFactor Again Named One of THE BEST Suppliers in the Semiconductor Industry FormFactor Receives Five Star Rating in Annual Customer Satisfaction Survey LIVERMORE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading semiconductor test and measurement supplier, announced that it has again been named a top performer in TechInsights’ customer satisfaction survey earning five stars in three categories: 10 BEST Focused Suppliers of Chip Making Equipment,THE BEST Suppliers of Test Subsystems, andTHE BEST Suppliers of Assembly Test Equipment. In this survey,...
OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Ann...
OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting Reinforced Long-Term Commitment as Emerald Sponsor WARSAW, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the combined 2024 Pediatric Orthopaedic Society of North America (“POSNA”) and European Paediatric Orthopaedic Society (“EPOS”) annual meeting as an Emerald sponsor. At the Annual Meeting, the Company highlighted its growing portfolio...
Leslie’s, Inc. Appoints Maile (Clark) Naylor to Board of Directors
Leslie’s, Inc. Appoints Maile (Clark) Naylor to Board of Directors PHOENIX, May 15, 2024 (GLOBE NEWSWIRE) -- Leslie's, Inc. ("Leslie's" or the “Company”; NASDAQ: LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, announced that the Company has appointed Maile (Clark) Naylor to its Board of Directors, replacing Eric Kufel, effective May 15, 2024. Ms. Naylor has joined as a Class I Director and member of the Audit and Compensation Committees. Mr. Kufel has resigned from his board duties at Leslie’s to concentrate on his recently appointed ro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.